These results indicate that COX2 inhibition represents a novel, low-cost and low-toxicity drug-repurposing strategy to overcome therapeutic resistance in BRAFV600E CRC: supplementing standard-of-care encorafenib + panitumumab with celecoxib durably improves tumor growth inhibition. This evidence concerns the gene PTGS2 and neoplasm.